Status:

RECRUITING

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

Lead Sponsor:

Massachusetts General Hospital

Conditions:

NASH - Nonalcoholic Steatohepatitis

Eligibility:

FEMALE

45-70 years

Phase:

PHASE3

Brief Summary

Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited. Preclinical and preliminary clinical data suggest that estroge...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Postmenopausal women 45-70 years old
  • NASH by biopsy or NAFLD by imaging within 6 months of screen
  • Hepatitis C antibody and hepatitis B surface antigen negative
  • Negative mammogram within 1 year
  • Exclusion criteria:
  • Heavy alcohol use
  • Use of NASH pharmacotherapies within 12 months of study entry
  • Known cirrhosis, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam
  • Participation in NASH clinical trial within 6 months of study entry
  • Chronic use of corticosteroids, methotrexate, amiodarone, or tamoxifen within 6 months of entry
  • Known diagnosis of chronic liver disease other than NAFLD or found on biopsy
  • Contraindication to liver biopsy including INR \> 1.5, platelets \< 50,000/mL, ascites, chronic anticoagulation (other than aspirin), biliary obstruction, peritonitis, inability to lie supine for 30 minutes
  • Hgb \< 10.0 g/dL or glomerular filtration rate \< 60 mL/min
  • Contraindications to estrogen therapy
  • Any vaginal bleeding, including spotting, within the last year
  • Active malignancy
  • Severe chronic illness
  • Use of estrogen or progesterone within a year of baseline visit
  • Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip

Exclusion

    Key Trial Info

    Start Date :

    December 2 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    May 31 2027

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT04833140

    Start Date

    December 2 2021

    End Date

    May 31 2027

    Last Update

    August 3 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114